MRI动态增强时间强度曲线与乳腺癌微血管密度的相关性研究

目的探讨MRI动态增强在乳腺癌检测中的应用。方法对80例乳腺癌疑似患者进行MRI平扫及动态增强扫描和病理标本组织学检测，绘制出ROI的DCE—MRI时间信号强度曲线（TIC），测量、计算病灶动态强化参数和肿瘤微血管密度（MVD）。结果（1）80例乳腺癌疑似患者经MRI扫描，发现80例患者（81处病灶）TIC曲线呈廓清型。（2）80例患者的DCE—MRI扫描结果与组织病理学诊断结果一致性较高，呈正相关（r=0．935，P〈0．05）；（3）乳腺癌癌组织部分微血管密度（MVD）计数为34．74±12．05，明显高于正常组织18．36±3．16（t=6．47，P〈0．05）；（4）80例乳腺癌DCE-MRI扫描最大增强线形斜率ss值为2．38±0．40，增强峰值PH为（619．22±123．53）HU，与MVD呈正相关（r=0．72，P〈0．05；r=0．66，P〈0．05）；信号强度峰值时间Tpeak为（56．10±10．13）t／s，与MVD呈负相关（r=-0．53，P〈0．05）。结论DCE—MRI参数能间接反映乳腺癌血管生成状况．有望成为非创伤性早期发现和诊断乳腺癌的萤耍手段。

Relationship between TIC of DCE-MRI and angiogenesis in breast cancer

Objective To study the clinical application of magnetic resonance imaging （MRI） and dynamic contrast enhancement in the old breast cancer patients. Methods Eighty cases of elderly pa- tients with suspected breast cancer were detected by dynamic enhanced MRI, dynamic contrast enhanced MRI, and pathological examination. Results （1） Among 80 cases of suspected breast cancer patients, MRI scan found that the TIC curve of 80 patients （81 lesions） was entered a type curve. （2）DCE-MRI scan find- ings were highly consistent with histopathological diagnosis with a significant correlation （ r = 0. 935, P 〈 0. 05 ）. （3）The micro-vessel density（ MVD ; 34. 74 ± 12.05 ） in breast carcinoma - bearing tissues was significantly higher than the normal tissues adjacent to carcinoma （ 18.36 ± 3.16） （ t = 6.47, P 〈 0. 05 ）. （4） The value of DCE-MRI scan maximum enhancement linear slope （SS） and enhanced peak PH were 2. 38±0.40 and （619. 22± 123.53）HU, respectively. A significantly positive correlation was found between SS and MVD （ r = 0. 72, P 〈 0.05 ） and between PH and MVD （ r = 0. 66, P 〈 0. 05 ） , respectively. A significantly negative correlation was found between the signal intensity peak time （Tpeak; 56. 10 ± 10. 13 ） and MVD （ r = - 0. 53, P 〈 0. 05 ）. Conclusions DCE-MRI can indirectly reflect the status of angiogen- esis in breast cancers. It would be an important approach for the non - traumatic early detection and diagnosis of breast cancer.